Phase 3 reports
Phase 3 reports in metronomic therapy
21 publications that report or discuss phase 3 trials, newest first. Positive, negative, and mixed results are all listed.
Compiled automatically by Metronomic.com from PubMed and ClinicalTrials.gov. Automated listing. Each item links to its original source. Last refresh: Nov 15, 2026
Titles appear as published. A listing is not an endorsement, and a single study rarely settles a question. Not medically reviewed. Educational information, not medical advice.
Three recent phase 3 results are summarized in plain language on the home page.
- Phase 3 trialNat Cancer2026 JulLong-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 study.Tao YL, et al.
- Phase 3 trialJCO Glob Oncol2026 JunIntegrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS).Kapoor A, et al.
- StudyChin Clin Oncol2026 FebThe phase III MECCA study on metronomic chemo-endocrine therapy in advanced breast cancer-the results that so many have been waiting for.Wysocki PJ
- Phase 3 trialLancet Oncol2025 DecMetronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial.Yuan J, et al.
- Meta-analysisHead Neck2025 NovEfficacy and Safety of Adjuvant Capecitabine in Locoregionally Advanced Nasopharyngeal Carcinoma: A Meta-Analysis of Phase III Randomized Trials With Subgroup Analysis by Neoadjuvant Chemotherapy.Ben Kridis W and Khanfir A
- Phase 3 trialCancer Lett2025 Jul 1Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomes.Kothari R, et al.
- Phase 3 trialJCO Glob Oncol2025 MayTriple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study).Kapoor A, et al.
- Phase 3 trialJ Clin Oncol2025 Apr 10Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial.Hong RX, et al.
- Phase 3 trialPediatr Blood Cancer2025 AprResults of the Latin American Pediatric Oncology Group (GALOP-2011) Trial for Patients With Localized Ewing Sarcoma: A Multicentric Study of Interval-Compressed Multiagent Chemotherapy.Gregianin LJ, et al.
- Phase 3 trialNat Commun2022 May 12CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer.Filippone MG, et al.
- Phase 3 trialLancet2021 Jul 24Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.Chen YP, et al.
- Phase 3 trialLancet Glob Health2020 SepLow-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial.Patil V, et al.
- Phase 3 trialActa Neuropathol2020 FebRisk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials.Liu APY, et al.
- Phase 3 trialBreast Cancer Res Treat2018 JulMutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.Munzone E, et al.
- Phase 3 trialBMC Cancer2016 Oct 10SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.Rochlitz C, et al.
- Phase 3 trialBreast Cancer Res Treat2016 JulTumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.Pruneri G, et al.
- Phase 3 trialAnn Oncol2016 JanA randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial.Hagman H, et al.
- StudyAnn Transl Med2015 NovMetronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study.Nasr KE, et al.
- CommentaryNat Rev Clin Oncol2015 JunGastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials.Kerbel RS and Grothey A
- Phase 3 trialBreast2013 AprAdjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial.Crivellari D, et al.
- Phase 3 trialBlood2006 Jul 15Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy.Mancuso P, et al.
